Compare
Opko Health, Inc. vs Insmed Inc vs HUTCHMED (China) Ltd vs Pacira BioSciences, Inc.
| Latest fiscal year | Opko Health, Inc. OPK | Insmed Inc INSM | HUTCHMED (China) Ltd HCM | Pacira BioSciences, Inc. PCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $606.88M | $606.42M | $548.51M | $726.41M |
| Revenue growth (YoY) | -14.9% | +66.7% | -13.0% | +3.6% |
| Gross margin | 33.9% | 79.7% (computed) | 38.7% (computed) | 79.4% (computed) |
| Operating margin | -19.3% | -205.6% | -7.1% | 2.6% |
| Net margin | -37.2% | -210.5% | 83.3% | 1.0% |
| Net income | -$225.68M | -$1.28B | $456.91M | $7.03M |
| EPS (Diluted) | -$0.30 | -$6.42 | $0.52 | $0.16 |
| Operating cash flow | -$178.54M | -$935.01M | -$64.66M | $151.99M |
| Free cash flow | -$190.82M | -$967.58M | -$78.81M | $136.66M |
| Cash & equivalents | $364.41M | $510.44M | $71.33M | $158.54M |
| Total assets | $1.93B | $2.26B | $1.75B | $1.26B |
| Total liabilities | $663.99M | $1.53B | $501.83M | $571.81M |
| Shareholders' equity | $1.27B | $738.98M | $1.25B | $693.11M |
| Return on year-end equity | -17.8% | -172.8% | 36.5% | 1.0% |
| Shares outstanding | n/a | 214.26M | n/a | 41.12M |
Revenue, most recent five fiscal years
| Fiscal year | Opko Health, Inc. | Insmed Inc | HUTCHMED (China) Ltd | Pacira BioSciences, Inc. |
|---|---|---|---|---|
| Latest | $606.88M Ended 2025-12-31 | $606.42M Ended 2025-12-31 | $548.51M Ended 2025-12-31 | $726.41M Ended 2025-12-31 |
| 1 year earlier | $713.14M Ended 2024-12-31 | $363.71M Ended 2024-12-31 | $630.20M Ended 2024-12-31 | $700.97M Ended 2024-12-31 |
| 2 years earlier | $863.50M Ended 2023-12-31 | $305.21M Ended 2023-12-31 | $838.00M Ended 2023-12-31 | $674.98M Ended 2023-12-31 |
| 3 years earlier | $1.00B Ended 2022-12-31 | $245.36M Ended 2022-12-31 | $426.41M Ended 2022-12-31 | $666.82M Ended 2022-12-31 |
| 4 years earlier | $1.77B Ended 2021-12-31 | $188.46M Ended 2021-12-31 | $356.13M Ended 2021-12-31 | $541.53M Ended 2021-12-31 |